Currently Viewing:
Currently Reading
Patients With AML Have Significantly Lower Early Mortality at NCI-Designated Cancer Centers
March 17, 2018 – Laura Joszt
This Week in Managed Care: March 16, 2018
March 16, 2018
Despite Increasing Rates of PrEP Usage, Disparities Remain Among African Americans, Latinos
March 16, 2018 – Jaime Rosenberg
COPD Study Fails to Find Model That Can Predict Exacerbations
March 16, 2018 – Allison Inserro
5 Takeaways From the American College of Cardiology Scientific Session
March 16, 2018 – Mary Caffrey
AJMC® in the Press, March 16, 2018
March 16, 2018 – AJMC Staff
What We're Reading: Idaho, CMS Talk Again; Drug Pricing Poll Answers Vary; Senators Want 340B Info
March 16, 2018 – AJMC Staff
Battle Heats Up Over Insurance Stabilization as Abortion Gets Added Into the Mix
March 15, 2018 – Allison Inserro
FDA Takes Step to Reduce Smoking Rates, Proposes Lowering Nicotine Levels in Cigarettes
March 15, 2018 – Jaime Rosenberg

Study Finds Oncology Care Is Cheaper in Community Settings Than Hospital-Based Practices

Jaime Rosenberg
Authors of the study found that the mean total, chemotherapy, and physician costs were all lower in community settings compared with hospital-based settings for patients with breast, lung, and colorectal cancer. There were also fewer emergency department visits both 3 and 10 days following treatment.
A new study has found that oncology care in hospital outpatient settings is more expensive than independent community oncology practices.

During a webinar, “Oncology Site of Care Cost Difference & Solutions,” Lucio Gordan, MD, Medical Director, Division of Quality & Informatics, Florida Cancer Specialists & Research Institute, discussed his recently published study, ““The Value of Community Oncology: Site of Care Cost Analysis.”

Gordan began by identifying the barriers to high-quality care many cancer patients face. First, there is a limited oncology work force, he said. There is a substantial amount of retiring physicians and hematologists, and it is difficult to replace them, causing a shortage. In addition, we have an aging population and many clinics in rural settings are closing because they have difficulty recruiting and retaining physicians.

Next, many have difficulty accessing affordable healthcare coverage, said Gordan. There are premium increases, disappearances of preferred provider organizations, and an unavailability of public health exchanges. Last, there is an economic strain due to economic costs, shifting payment models, practice consolidation, and administrative and regulatory changes.

According to Gordan, 75% of community practices have been acquired by hospital networks, which previous research has suggested leads to higher costs for patients.

“We are very concerned with the rapid shift from community-based oncology practices to hospital-acquired practices,” said Gordan. “We see an explosion of cost.”

The study, coauthored by Gordan and Marlo Blazer, PharmD, BCOP, Xcenda, an AmerisourceBergen Company, utilized a matched analysis of patients treated in community settings versus outpatient hospital settings for breast, lung, and colorectal cancer.

The matched analysis accounted for specific chemotherapy regimen received, receipt of radiation therapy during treatment, presence of metastatic disease, gender, surgery, and geographical difference.

The authors included 10% of a random sample of medical and pharmacy claims from the IMS LifeLink database. The database included longitudinal and integrated pharmaceutical claims for over 80 million patients from 70 health plans. The study included 6675 patients receiving chemotherapy, radiation, and/or surgery for the 3 types of cancer between July 10, 2010, and June 20, 2015. The first date of chemotherapy served as the index date for each patient.

The authors analyzed both cost differentials between each setting and the quality of care outcomes.

Results showed that the mean total price per month per patient for community practices was $12,548, whereas the mean total for hospital-based practices was $20,060, an almost $8000 difference. Chemotherapy costs were $4933 per patient per month for community-based practices, compared with $8443 for hospital-based practices. The cost of physician visits for community practices was $765 and for hospital-based practices was $3316.

Community practices also saw 28% fewer emergency department visits 3 days post-treatment and 18% fewer emergency department visits after 10 days.

The findings of this study were consistent with those of 10 previous studies conducted between 2011 and 2016.

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!